Prognostic implication of macrocytosis on adverse outcomes after coronary intervention

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 148-153

  Myojo, Masahiro ^a   Iwata, Hiroshi ^a   Kohro, Takahide ^a   Sato, Hiroki ^b   Kiyosue, Arihiro ^a   Ando, Jiro ^a   Sawaki, Daigo ^a   Takahashi, Masao ^a   Fujita, Hideo ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

Author keywords

Anemia; Coronary intervention; Erythrocyte abnormalities; Macrocytosis; Risk stratification

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; AGED; ANEMIA; ARTICLE; BODY MASS; DRUG USE; FEMALE; HEART DEATH; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEDICAL RECORD REVIEW; MEGALOCYTOSIS; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; STROKE;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; ERYTHROCYTE INDICES; ERYTHROCYTES, ABNORMAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857031820     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.044     Document Type: Article

References (22)

1. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
2. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
3. Tsantes A.E., Bonovas S., Travlou A., Sitaras N.M. Redox imbalance, macrocytosis, and rbc homeostasis. Antioxid Redox Signal 2006, 8:1205-1216.
4. Japanese Society for Dialysis Therapy (JSDT) Guideline for renal anemia in chronic kidney disease. Toseki Kai-shi 2008, 41:661-716.
5. Khusun H., Yip R., Schultink W., Dillon D.H. World health organization hemoglobin cut-off points for the detection of anemia are valid for an indonesian population. J Nutr 1999, 129:1669-1674.
6. Group W.S. Nutritional anemias: report of a WHO scientific group 1968, World Health Organization, Geneva, Switzerland.
7. Mancia G., De Backer G., Dominiczak A., et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). J Hypertens 2007, 25:1105-1187.
8. Genest J., McPherson R., Frohlich J., et al. 2009 canadian cardiovascular society/canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
9. Kolberg J.A., Jorgensen T., Gerwien R.W., et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the inter99 cohort. Diabetes Care 2009, 32:1207-1212.
10. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001, 344:1117-1124.
11. Shinohara Y., Yamaguchi T. Outline of the japanese guidelines for the management of stroke 2004 and subsequent revision. Int J Stroke 2008, 3:55-62.
12. Colon-Otero G., Menke D., Hook C.C. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin North Am 1992, 76:581-597.
13. Breedveld F.C., Bieger R., van Wermeskerken R.K. The clinical significance of macrocytosis. Acta Med Scand 1981, 209:319-322.
14. Davidson R.J., Hamilton P.J. High mean red cell volume: its incidence and significance in routine haematology. J Clin Pathol 1978, 31:493-498.
15. Morris M.S., Jacques P.F., Rosenberg I.H., Selhub J. Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in american seniors. Am J Clin Nutr 2010, 91:1733-1744.
16. Shishehbor M.H., Filby S.J., Chhatriwalla A.K., et al. Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia. JACC Cardiovasc Interv 2009, 2:329-336.
17. Sangoi M.B., Da Silva S.H., da Silva J.E., Moresco R.N. Relation between red blood cell distribution width and mortality after acute myocardial infarction. Int J Cardiol 2011, 146:278-280.
18. Aslinia F., Mazza J.J., Yale S.H. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res 2006, 4:236-241.
19. Savage D.G., Ogundipe A., Allen R.H., Stabler S.P., Lindenbaum J. Etiology and diagnostic evaluation of macrocytosis. Am J Med Sci 2000, 319:343-352.
20. Lucantoni G., Pietraforte D., Matarrese P., et al. The red blood cell as a biosensor for monitoring oxidative imbalance in chronic obstructive pulmonary disease: an ex vivo and in vitro study. Antioxid Redox Signal 2006, 8:1171-1182.
21. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury. Part II. Animal and human studies. Circulation 2003, 108:2034-2040.
22. Coccia R., Spadaccio C., Foppoli C., et al. The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study. Clin Ther 2007, 29:1706-1717.